Share Page

Multimedia

Discover NIMH: Drug Discovery and Development

October 9, 2019

One of the most exciting recent breakthroughs from research funded by the National Institute of Mental Health (NIMH) is the development of a fast-acting medication for treatment-resistant depression based on ketamine. This treatment is bringing new hope to people and families affected by major depression.

Mental Illnesses and COVID-19 Risks April 29, 2022
Panic Disorder: The Symptoms March 30, 2022
Director’s Innovation Speaker Series: Beyond FDA Approval: Assessing the Value of New Health Technologies March 8, 2022
Mental Health and Older Adults Facebook Live Q&A March 1, 2022

: Anxiety Disorders; Attention-Deficit/Hyperactivity Disorder (ADHD); Autism Spectrum Disorder (ASD); Bipolar Disorder; Borderline Personality Disorder; COVID-19; Depression; Disruptive Mood Dysregulation Disorder; Eating Disorders; Generalized Anxiety Disorder; HIV/AIDS; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Psychosis; Schizophrenia; Social Anxiety Disorder; Suicide; Traumatic Events

Mental Illnesses and COVID-19 Risks April 29, 2022
Mental Health and Older Adults Facebook Live Q&A March 1, 2022
Get to Know Your Brain February 18, 2022
Workshop: Nonaffective Psychosis in Midlife and Beyond - Day 2 February 10, 2022

: Children and Adolescents; Global Mental Health; Men’s Mental Health; Military Service Members; Older Adults; Sexual and Gender Minority; Women’s Mental Health

: Basic Research; Brain Anatomy and Physiology; BRAIN Initiative; Clinical Research and Trials; Genetics; Health Disparities; Mental Health Services Research; Prevention; RDoC; Recovery Act; Research Funding; Training; Treatments

The View of the NIMH Intramural Program From the Top: An Interview with Dr. Susan Amara May 13, 2021
Message from the Director on the Strategic Plan for Research April 29, 2020
Strategic Plan for Research Overview April 29, 2020
About NIMH April 29, 2020

: Institute Announcements